TFF Pharmaceuticals raises ~$1.2M in registered direct offering with warrants at $8.00/share

TFF Pharmaceuticals, Inc.

Sold 147,500 shares at $8.00 in registered direct offering; gross proceeds ~$1.2M.
Concurrent private placement of warrants to purchase 147,500 shares at $8.00; exercisable for 5.5 years.
H.C. Wainwright acted as sole placement agent; receives 7% cash fee and 10,325 warrants at $10.00.
Net proceeds to be used for working capital and general corporate purposes.
Closing occurred March 22, 2024; offering priced at-the-market under Nasdaq rules.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TFF Pharmaceuticals, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.

Action: entry
Agreement: underwriting
Counterparty: H.C. Wainwright & Co., LLC

Exact text from the filing

In connection with the Offering, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

TFF Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $1.2 million (effective 2024-03-20).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $1.2 million
Effective: 2024-03-20

Exact text from the filing

On March 20, 2024, TFF Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering priced at-the-market under the rules of the Nasdaq Stock Market (the “Registered Offering”), an aggregate of 147,500 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $8.00 per share (the “Shares”), for gross proceeds from the Registered Offering of approximately $1.2 million, before deducting the placement agent fee and estimated offering expenses.

View on SEC.gov

545 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-24-025167

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.